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AbstrACt
Objectives We aimed to develop a digital intervention to 
support antidepressant discontinuation in UK primary care 
that is scalable, accessible, safe and feasible. In this paper, 
we describe the development using a theory, evidence and 
person- based approach.
Design Intervention development using a theory, evidence 
and person- based approach.
setting Primary Care in the South of England.
Participants Fifteen participants with a range of 
antidepressant experience took part in ‘think aloud’ 
interviews for intervention optimisation.
Intervention Our digital intervention prototype (called 
‘ADvisor’) was developed on the basis of a planning 
phase consisting of qualitative and quantitative reviews, 
an in- depth qualitative study, the development of guiding 
principles and a theory- based behavioural analysis. Our 
optimisation phase consisted of ‘think aloud’ interviews 
where the intervention was iteratively refined.
results The qualitative systematic review and in- depth 
qualitative study highlighted the centrality of fear of 
depression relapse as a key barrier to discontinuation. 
The quantitative systematic review showed that 
psychologically informed approaches such as cognitive–
behavioural therapy were associated with greater rates of 
discontinuation than simple advice to reduce. Following 
a behavioural diagnosis based on the behaviour change 
wheel, social cognitive theory provided a theoretical basis 
for the intervention. The intervention was optimised on 
the basis of think aloud interviews, where participants 
suggested they like the flexibility of the system and found 
it reassuring. Changes were made to the tone of the 
material and the structure was adjusted based on this 
qualitative feedback.
Conclusions ‘ADvisor’ is a theory, evidence and 
person- based digital intervention designed to support 
antidepressant discontinuation. The intervention was 
perceived as helpful and reassuring in optimisation 
interviews. Trials are now needed to determine the 
feasibility, clinical and cost- effectiveness of this approach.
IntrODuCtIOn
The number of antidepressant prescriptions 
in the UK has continued to rise over the 
past four decades,1 a trend which has also 
been seen in the USA and across Europe.2 3 
Approximately 10% of adults in the UK are 
currently prescribed antidepressant medica-
tion.4 Though antidepressants can prevent 
relapse, there is evidence that 30%–50% of 
patients on long- term antidepressants have 
no indication based on guidelines for long- 
term use.5–7 Research suggests this increase in 
prescribing is primarily due to general prac-
titioners (GPs) prescribing antidepressants 
for longer and longer durations over time.8 
Long- term antidepressant use is both costly 
to the UK National Health Service (NHS) (in 
terms of prescription and appointment costs) 
strengths and limitations of this study
 ► A systematic review and qualitative meta- synthesis 
were conducted alongside primary qualitative work 
to guide the content of the intervention.
 ► A theory- based behavioural analysis and the devel-
opment of guiding principles further informed the 
planning phase of intervention development.
 ► Think aloud interviews provided in- depth under-
standing of patients’ views of the intervention in 
terms of usability and content.
 ► The intervention was iteratively refined throughout 
the think aloud interviews to produce an intervention 
that aligns with patient preference.
 ► Think aloud participants were predominantly white 
British and from more affluent regions in the South 
of England and may not represent the views of all 
antidepressant users.
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and is associated with increased side effects.9 Attempting 
to discontinue antidepressants in the 30%–50% with no 
indication for long- term use may, therefore, be beneficial 
to patients and positively impact on use of healthcare 
resources.
There are many factors that may contribute to long- 
term antidepressant use, including the occurrence of a 
physiological withdrawal syndrome following reduction or 
cessation and psychological factors such as beliefs about 
the necessity of long- term use and fear of relapse.10 Infre-
quent reviews of patients taking antidepressants may also 
contribute to sustained use.11 However, simply prompting 
for patient reviews has resulted in discontinuation rates 
of 6%–8%, not significantly differing from usual care.12 13 
This highlights the potential importance of psychologi-
cally informed interventions to support withdrawal.
Trials have shown that cognitive–behavioural therapy 
(CBT) and mindfulness- based cognitive therapy (MBCT) 
can effectively support discontinuation of antidepres-
sants, with cessation rates ranging from 55% to 95%.14–18 
Although producing positive outcomes, these interven-
tions involve intensive group/face- to- face courses, thus 
access and ability to scale up within resource- strapped 
health services may be severely limited. There is a need 
for accessible, scalable psychologically informed inter-
ventions that can effectively support individuals where 
discontinuation is appropriate.
In the UK, 89% of the general population in 2018 used 
the internet weekly, up from 55% in 2006.19 Internet- 
based digital interventions supported with human 
contact have been shown to effectively reduce depres-
sion and anxiety.20 Digital intervention may have poten-
tial to provide a scalable, accessible way of supporting 
appropriate antidepressant discontinuation. We aimed to 
develop such a supported digital intervention as part of 
the UK- based REviewing long term antiDepressant Use 
by Careful monitoring in Everyday practice (REDUCE) 
programme to develop and trial safe, feasible and effec-
tive ways to support patients withdrawing from antide-
pressants where appropriate.
In this paper, we describe the planning and optimisa-
tion of our patient- facing digital intervention to support 
discontinuation, named ‘ADvisor’. This paper provides 
an overview of the different stages of development and 
how these together informed a digital intervention. Some 
of this work has implications beyond intervention devel-
opment and further details are, therefore, published else-
where. This paper is instead focused on the particular 
work involved in developing a digital intervention.
MethODs
Phase 1: intervention planning and development
There is a range of systematic protocols for interven-
tion development that can be drawn on at the outset of 
a development project (eg, intervention mapping21). 
We chose to implement a theory, evidence and person- 
based approach (PBA).22 This comprehensive strategy 
integrates the PBA23 24 with more commonly used theory 
and evidenced- based methods. The PBA provides guid-
ance for integrating systematic in- depth qualitative 
research into the development process. Drawing on the 
PBA ensures evidence and theory- based techniques are 
applied with a full understanding of the target users’ 
perspectives and psychosocial context.23 We will outline 
the components of our comprehensive approach 
including systematic reviewing, primary qualitative 
research, development of guiding principles, behavioural 
analysis and logic modelling.
Systematic reviewing
Two systematic reviews were conducted: a quantitative 
review with meta- analysis, and a qualitative thematic 
synthesis, described in detail elsewhere.10 25
The qualitative review searched nine databases from 
inception to February 2017 and updated searches were 
carried out in July 2018. Citation searching, reference 
list checking and related article checking were also 
performed. The quantitative review involved searching 
eight databases from inception to March 2017. Citations 
and reference lists were searched for full papers that met 
the inclusion criteria. Both searches were developed by 
an experience librarian and systematic reviewer. Further 
details of the search strategies can be found in the full 
publications of these reviews.10 25
For intervention planning, from the quantitative 
review, we drew out interventions that had successfully 
supported discontinuation and considered their interven-
tion components, seeking full manuals where possible. 
We aimed to determine which components could be best 
translated into a digital format. In the qualitative review, 
we identified barriers and facilitators to antidepressant 
discontinuation. Barriers and facilitators were tabulated 
and used to inform the ‘guiding principles’ section as well 
as content for the intervention.
Primary qualitative research
Individual semistructured interviews were conducted by 
SW with primary care patients with varying experiences 
of antidepressants, and varying levels of motivation to 
stop, with the aim to explore experiences of antidepres-
sant discontinuation. These interviews explored patients’ 
views on barriers and facilitators to withdrawal, the role 
of healthcare professionals in supporting withdrawal 
attempts and elements of a proposed intervention to 
support withdrawal. Interviews were conducted at the 
patients’ homes or their GP practices and were audio 
recorded and transcribed verbatim. Patients provided 
written consent to take part. Analysis was conducted, 
following thematic analytical principles suggested by 
Braun and Clarke,26 and Joffe and Yardley.27 Analysis was 
conducted by SW (a qualitative researcher). The coding 
manual and developed themes were discussed and 
agreed by the wider development group. Only the find-
ings related to the development of the intervention are 
described in this paper. Further details of the methods 
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and the findings related to the broader aims of this piece 
of qualitative work will be published elsewhere.
Development of guiding principles
Guiding principles are a fundamental part of the PBA.23 
They represent broad design objectives that guide the 
application/implementation of the core intervention 
strategies, aiming to increase engagement.24 Guiding prin-
ciples were developed based on the qualitative synthesis10 
and primary qualitative findings. Through this qualitative 
work, we aimed to identify key behavioural needs, chal-
lenges or issues the intervention needed to address.
Behavioural analysis
Behavioural and implementation theory was drawn on as 
we triangulated between the qualitative and quantitative 
evidence, and the expert views of our team (including 
patient representatives, GPs, psychiatrists, psycholo-
gists, sociologists and health services researchers) to 
determine important intervention components. Using 
the behaviour change wheel (BCW) and COM- B model 
of behaviour (capability, opportunity, motivation- 
behaviour),28 informed by our qualitative research, we 
conducted a ‘behavioural diagnosis’.29 In behavioural 
diagnosis, factors that are likely to affect the central 
target behaviour are considered in terms of capability, 
opportunity, and motivation.28 29 Once we had proposed 
initial intervention content/components, these were 
mapped theoretically using the BCW, social cogni-
tive theory (SCT)30 and normalisation process theory 
(NPT).31 As well as providing a mapped full description 
of the proposed intervention, this process ensured we 
did not miss areas of theory that may have improved the 
intervention.
Phase 2: intervention optimisation
Design
Within the PBA, ‘think aloud’ qualitative studies are 
employed to optimise the prototype intervention. Think 
aloud studies are designed to elicit in- depth perspec-
tives about the nature of the content, rather than solely 
focusing on functionality and usability.
Participants
Participants were recruited from eight primary care 
practices in the South of England. Eligibility criteria 
were as follows: inclusion criteria: Taking antidepres-
sants for more than 1 year for a first episode or 2 years 
for a subsequent episode; discontinued antidepres-
sants, or were in the process of tapering. Exclusion 
criteria: Patient Health Questionnaire (PHQ)-9 scores 
greater than or equal to 10 (suggesting persisting 
symptoms of depression) and those who reported any 
suicide ideation; history of suicide attempts; ongoing 
social difficulties or recent life events likely to provoke 
relapse; more than three previous significant episodes 
of depression; comorbid psychosis, bipolar disorder, 
obsessive–compulsive disorder or substance use (or 
history of these conditions) or currently receiving 
psychiatric treatment.
Procedure
Eligible participants met with a researcher (HMB, SW 
or TK) either in their own home or at their primary 
care practice where they provided written consent to 
take part in a think- aloud interview. Interviews invited 
participants to engage with the prototype intervention 
using a study laptop and say what they were thinking, 
aloud in real time. The interviewer prompted partici-
pants when necessary (eg, asking patients ‘How do you 
feel about the information on this page?’). Interviews 
ranged from 38 to 93 min in length and were audio 
recorded and transcribed verbatim. The interview 
ended when patients concluded they had looked at all 
the information they would like to see or if the interview 
length was approaching 90 min. The amount of inter-
vention content the patient saw, therefore, depended 
on their own preferences and the time they took to 
look at the information. The interview schedule can 
be found in online supplementary appendix A. There 
were three primary iterations of interviews based on 
three key modified prototype interventions. Patients at 
the start of the study, therefore, saw different versions 
of the intervention to those who were recruited later 
rounds. This allowed the changes made as a result of 
patient feedback to continue to be tested. Interviews 
with patients continued until data saturation was 
reached, defined here as when comments about the 
intervention reflected that no further changes were 
necessary according to the PBA and when there were 
no new codes identified as part of the thematic analysis.
Analysis
Transcribed interviews were analysed using two primary 
analytic methods. The first analytical method was 
a more rapid coding than thematic analysis, which 
involves using coding tables designed for the PBA, 
where positive and negative comments were tabulated. 
Core problematic issues likely to affect participant 
engagement or intervention effectiveness identified 
using this coding method were brought to the broader 
group, and amendments to the intervention agreed. 
Alongside this method, a more in- depth thematic anal-
ysis26 27 was developed to capture patient views of the 
intervention and ideas about how they might engage 
with it, beyond comments on what might be amended. 
For this latter analysis, HMB independently coded the 
transcripts and discussed a preliminary coding frame 
with a second researcher (AWAG). Theme labelling and 
interpretation were discussed and agreed by the team. 
The thematic analysis is presented here. Therefore, 
while the initial analysis informed what changes were 
necessary, the thematic analysis explored what patients 
thought about the intervention in greater depth. These 
analyses were related in that some things that were 
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Table 1 Guiding principles for the ADvisor intervention
ADvisor guiding principles
Design objectives Key (distinctive) design features
To build confidence that discontinuing 
antidepressant medication is safe and achievable 
over the long term
 ► Offer an evidence- based rationale for how withdrawal and replacement 
with psychological/behavioural alternatives will help.
 ► Provide withdrawal success stories and examples (modelling).
 ► Address concerns patients may have re withdrawal (side effects, 
symptoms) from their previous experiences—demonstrate empathy and 
acknowledge real barriers to change.
 ► Offer motivational support.
To be an accessible, motivating resource that 
supports patients in managing their withdrawal in a 
manner that aligns with their preferences
 ► Foster autonomy through choice and a non- prescriptive approach, 
providing explanations for all suggestions.
 ► Offer a broad range of strategies from quick support in managing 
withdrawal symptoms, to more in- depth modules on a mindful 
approach to preventing depression relapse, and behavioural strategies 
for managing day- to- day stressors.
 ► Provide options for self- tailoring to personal experiences and barriers
 ► Provide a simple, attractive interface, with a focus on accessibly of 
content
identified in our initial analysis informed the develop-
ment of themes.
results
Phase 1: intervention planning and development
Systematic reviewing
Our qualitative thematic synthesis (see ref. 10 for 
full results) across 22 studies highlighted key barriers 
and facilitators to discontinuation. Patients’ concerns 
regarding their ability to cope and psychological depen-
dence were common barriers, as were difficulties expe-
rienced in previous stopping attempts. Confidence in 
abilities to stop, effective coping strategies and stable 
life circumstances facilitated discontinuation. Additional 
important themes included fear of relapse—this was the 
central fear that prohibited stopping attempts—and 
beliefs about depression. The belief that depression was 
a long- term condition caused by biochemical changes 
in the brain was a key barrier to discontinuation. Where 
patients reported a very different belief that depression 
was due to changing life circumstances, this seemed to 
facilitate discontinuation. Patients’ self- identity and goals 
were an important factor: Having self- identifying as ‘old’ 
or ‘disabled’ acted as a barrier to discontinuation, and 
having goals to function independently functioned as 
facilitator to discontinuation.
In the quantitative systematic review (see ref. 25 for full 
results), a variety of therapeutic techniques were imple-
mented including a patient- specific letter to the GP with 
a recommendation to discontinue plus tapering advice; 
GP review of the patient’s condition and medication; 
CBT plus tapering; MBCT with tapering support gradual 
discontinuation and 1- week tapering. The results indi-
cated that CBT or MBCT plus tapering are helpful for 
patients discontinuing antidepressants, with cessation 
rates of 40%–95%,23 compared with only 6%–8% cessa-
tion where health professionals are simply prompted 
to review patients. CBT plus tapering resulted in lower 
relapse rates compared with clinical management plus 
taper (15%–25% vs 35%–80%).23 The content of the 
interventions was extracted and feasibility of delivery in 
a digital format was considered. We developed a module 
based closely on MBCT protocols on the basis of this 
review.
The findings from both reviews’ findings informed the 
guiding principles, behavioural analysis and logic model, 
which formed the basis for intervention content selection 
and development.
Primary qualitative research
Five themes were developed through the thematic analysis 
of 19 patient interviews (full details will be published else-
where). A summary is presented here. Participants spoke 
of the centrality of personal medication and healthcare 
factors, for example, some patients described the need 
for a personalised tapering regimen to support them 
discontinuing. Beliefs about depression and its treatment 
were key in shaping participants’ stance towards discon-
tinuing. For example, ideas around the necessity of anti-
depressant medication due to ‘chemical imbalance’ were 
common. Holding these beliefs made patients less likely 
to consider stopping. Fear of stopping, driven by fear of 
relapse were discussed as central barriers to withdrawal. 
The impact of others also appeared to be important. 
For example, the perception of stigma and the feeling 
of letting people down, made participants less willing to 
discontinue, while having a good support network was 
considered beneficial to stopping. Participants were also 
asked to consider digital methods of intervention delivery. 
Elements participants wanted to see in the intervention 
included explanation around how antidepressants work, 
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Figure 1 Logic model advisor intervention alongside additional components. ADs, antidepressants; GP, general practitioner; 
HP, health professional.
support for anxiety/fear of discontinuing, coping strate-
gies and information on withdrawal symptoms. There was 
some concern around privacy and around preference for 
greater face- to- face interaction to support them during 
the discontinuation phase. Patients expressed a need to 
have accessible, interactive and information presented in 
an aesthetically pleasing way.
The full findings in our primary qualitative research 
mirrored and expanded the findings of our qualitative 
thematic synthesis. They fed into the guiding principles, 
behavioural analysis, logic model and content for the 
intervention.
Guiding principles
On the basis of the qualitative work, guiding principles 
were developed (comprised of design objectives and 
design features) (see table 1). We developed two broad 
design objectives: The first, regarding building confi-
dence that discontinuing antidepressant medication 
is safe and achievable, was developed from prominent 
themes around fear of stopping, the need for confidence 
and beliefs that antidepressant medications are needed 
long term. The second objective that the intervention 
should be an accessible, motivating resource that supports 
patients in managing their withdrawal in a manner that 
aligns with their preferences, was developed in response 
to the range of views and beliefs held about the nature 
of depression and why antidepressants were necessary. 
Design features that support both these objectives are 
listed in table 1.
Behavioural analysis
Our behavioural diagnosis following the COM- B model 
can be found in online supplementary appendix B. Our 
target behaviour was reducing and stopping the taking 
of antidepressant medication. Based on our reviews, 
qualitative work and discussion among our broader 
team, psychological capability and reflective motivation 
were considered key constructs for changing the target 
behaviour. The results of our behavioural diagnosis are 
presented in online supplementary appendix B.
Following the drafting of module content and struc-
ture, we mapped content against (1) studies suggesting 
content would be important, (2) BCW constructs, (3) 
SCT and (4) NPT. See online supplementary appendix 
C for detailed theoretical mapping for our intervention 
content.
Fundamentally, SCT32 underlies the approach taken 
in the intervention to facilitate behavioural change. We 
ensured content aligned with the principles of SCT on 
how best to increase patient’s confidence that they will be 
able to safely stop antidepressants (eg, drawing on persua-
sion, modelling and supporting performance exposure). 
We also focused on modifying outcome expectations, for 
example, increase positive expectation that the recom-
mended strategies are likely to support effective discon-
tinuation. At a later stage in development, the Necessity 
Concerns Framework (NCF)33 was considered. NCF was 
developed to explain the role of treatment beliefs on 
adherence behaviours. According to NCF, adherence 
to treatment is a function of patients’ beliefs about the 
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Table 2 Outline content of the digital intervention
Content Description
Reducing and stopping 
antidepressants
An introduction to the intervention, which addresses motivations behind withdrawal, asking 
participants to reflect on why they might prefer to discontinue antidepressant treatment. Guidance on 
when to speak to their GP/nurse and advice on following a tapering regimen.
Thinking about 
antidepressants
Acknowledging that antidepressant treatment is not necessarily required long term and that the 
mechanisms are more complex than correcting a serotonin deficiency.
I’m worried about 
stopping
Addressing participant fears by signposting participants to appropriate resources in ADvisor.
Dealing with withdrawal 
symptoms
Guidance for dealing with mild withdrawal symptoms (including guided practices for accepting/
tolerating unpleasant symptoms). Advice for patients to contact their GP for assistance with 
moderate or severe withdrawal symptoms.
Keeping well Relapse prevention techniques grounded in mindfulness- based cognitive therapy.
Thinking about what 
you value
Reflection on values and committed action to values (through goal setting), based on acceptance and 
commitment therapy.
Moving forward Psychoeducation and techniques for managing distress (eg, mindfulness and behaviour activation) 
provided through a distress- management online intervention, Healthy Paths.
My notes Where patients can access content from other sections where they have written their own responses 
(eg, their own reasons for wanting to stop antidepressants and their own warning signs and triggers 
for relapse).
Resources Direct links to resources in ADvisor (eg, activity planning and information for family and friends).
GP, general practitioner.
necessity of their medication and the concerns they have 
about it; high necessity beliefs and low concerns are likely 
to predict medication adherence.34 In the context of anti-
depressant withdrawal, accordingly, we would need to 
reduce patients’ beliefs about the necessity of the medi-
cation, highlight likely benefits of stopping and reduce 
concern regarding the stopping process. All of these 
factors will ultimately impact on self- efficacy, hence the 
centrality of SCT in our theoretical modelling.
Logic modelling
Logic models represent proposed or hypothesised ‘theo-
ries of change’ outlining the problem/issue and barriers, 
ingredients mechanism and how these may affect target 
outcomes.35 We developed a draft logic model for the 
REDUCE patient intervention, drawing on theory, 
evidence- based and our person- based qualitative work, 
see figure 1.
Outline intervention content
On the basis of our planning process, a prototype digital 
intervention was developed for patients taking antide-
pressants long term (defined as more than 1 year for a 
first episode or more than 2 years following two or more 
episodes). The contents of the online intervention are 
described in table 2. A digital intervention for health 
professionals (providing information and guidance on 
antidepressant reduction) was also developed as part of 
the REDUCE programme and is reported separately.
Content was developed using findings from the reviews 
of the literature, primary qualitative work, behavioural 
analysis and logic modelling. In addition to online 
content, scheduled telephone support contacts with 
specialists trained in providing psychological support and 
email reminders were developed as part of the patient 
intervention.
When accessing the ADvisor intervention for the first 
time, users view a core module with the central rationale 
for stopping antidepressants; they can then access a menu 
with a range of further modules based on our planning 
work. Aligning with our guiding principles, users are 
advised that they can use ADvisor how and when they 
would like. It is their tool, to be used to support them in 
a way that is consistent with their needs, preferences and 
experience. Through this approach we aimed to maxi-
mise autonomous motivation.36
Content for the online intervention was initially drafted 
by a member of the content development team (HMB) 
before AWAG and MG and then wider team members 
offered their expertise and informed further develop-
ment of the content. This iterative process continued 
until all team members were satisfied that the proto-
type intervention addressed key experiences, barriers 
and facilitators identified by the work from phase one 
and were in line with the guiding principles, theoretical 
modelling and logic model. The content was transferred 
into online pages in LifeGuide ( www. lifeguideonline. org) 
and further amendments to the presentation were made 
by the team before moving forward to the optimisation 
phase.
Phase 2: intervention optimisation
Of the 42 patients who returned a postal reply slip 
expressing interest, 11 were ineligible, 9 could not subse-
quently be contacted, 2 later declined and 5 expressed an 
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Table 3 Think aloud qualitative study characteristics
Characteristics N (%)
Females 9 (60)
Males 6 (40)
Married 11 (73.3)
cohabiting 2 (13.3)
Single 2 (13.3)
Employed 9 (60)
Not currently in employment 6 (40)
Diagnosis   
Depression/low mood 9 (60)
Fibromyalgia 2 (13.3)
Unknown 2 (13.3)
Urethritis 1 (6.7)
Post- traumatic stress disorder 1 (6.7)
Successfully stopped before 8 (53)
Currently taking antidepressants 14 (93.3)
 Mean (SD)
Age 55.20 (15.59)
Years on antidepressants 10.43 (7.27)
PHQ-9 score 4.53 (2.50)
PHQ-9, Patient Health Questionnaire - 9.
interest only after data saturation had been reached. This 
resulted in a final sample of 15 patients (see table 3 for 
sample characteristics).
Iterations of advisor
There were three rounds of iterations of the interven-
tion during the think- aloud interviews. Patients in round 
1 were shown the first prototype. Changes made to the 
version in round 2 included making the tone less formal, 
revising the introduction navigation and the wording to 
be more gentle. The ‘my notes’ section was also reorgan-
ised to be clearer and buttons to exit the intervention at 
the end of each module were removed to try to keep the 
patients on site for longer. In the version shown in round 
3, some changes included further revision of the tone, 
some of the information was presented in a more aesthet-
ically pleasing way and some links within the intervention 
to other modules were removed as these were confusing 
for patients.
Findings
Six themes were developed, namely: flexible use; famil-
iarity with content; reassurance; utility of information; 
teaching of useful skills and feeling supported. Patient 
identifiers and demographic information are presented 
below each quote, where round number refers to the iter-
ation of the intervention that the patient saw.
Flexible use
Participants discussed how ADvisor could be used in 
different ways to suit the individual. When viewing the 
main menu page in ADvisor participants talked about 
how different sections would be more useful for them, 
and that some sections were not relevant for them at that 
particular time.
Dealing with withdrawal symptoms, I don’t have any, 
so it’s fine. That [keeping well and moving forward 
modules] I’m more interested in about because I 
think that’s—for me, keeping well and moving for-
ward is where I am and where I want to be.
[14/03/0001] [round 1]
Initial versions of the intervention included an intro-
duction module within which participants could choose 
which of two options they would like to view first, though 
they would need to view both sections before moving 
onto the main menu. Some participants felt that this was 
in contradiction to the aim of choice and flexibility. We, 
therefore, modified the intervention so that the intro-
duction was shorter and these two choices were moved to 
optional buttons in the main menu.
It’s kind of saying you’ve really got to look at that 
one; otherwise, you will have flicked back through or 
I would have thought it might have been, if it’s really 
flexible, user friendly, you might be allowed to skip 
that page because you could always revisit it again.
[01/01/0026] [round 1]
Participants not only varied in the topics they wanted 
to look at, but also in terms of the different exercises they 
would choose to engage with in ADvisor. Some partici-
pants liked the idea of writing down their responses in 
ADvisor while others did not.
No. That’s me. No, I’m very stoic and—just—I don’t 
need to write it down, it’s fine; I know what I’m doing, 
I’m fine, very much, I think.
[01/01/0005] [round 2]
I’d like to say that I would [write things down]; I think 
I probably would if I was—you know—really serious 
about it, because I like to write things down and if I 
haven’t written it down, it can just go out of my brain. 
So I think, for me, it would be important to write that 
down.
[05/01/0022] [round 2]
Participants also discussed how ADvisor could be used 
in different ways. For example, it can be something used 
regularly, something one can pick up as and when neces-
sary or it can be read through all in one go.
So it looks like you can use it when you want to but if 
you feel you’re coping without, so it’s not something 
you have to do all the time.
[05/01/0022] [round 2]
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Yes, I would use it for future reference, as well, be-
cause you can always go backwards, can’t you? With 
anything, I mean. If I ever came to a time where I was 
feeling down, I think, to go back on to something is 
to remind you. Because it’s easy to forget.
[13/01/0058] [round 3]
Familiarity with content
Many of the participants referred to previous experience 
with psychological therapies or tools they have used in 
the past for their symptoms of depression. When reading 
cognitive- behavioural, acceptance and commitment, or 
mindfulness- based information in ADvisor, participants 
expressed a sense of familiarity with the terminology or 
messages they were presented.
Clicking on Breathing Space; that’s very much mind-
fulness, isn’t it? Yes, I like that, that’s nice.
[14/03/0001] [ round 1]
Some of the information about depression and anti-
depressants seemed to be obvious to a small number of 
participants who had pre- existing knowledge, but they 
understood that not all patients would have the same 
prior knowledge. One participant in particular who 
worked in healthcare found that much of the information 
was not new to her.
I’m obviously interested in reducing still further or 
coming off the antidepressants. … See I don’t think 
I can—I do know an awful lot about it and read a lot 
about it and very—sorry—but, you know, being in the 
business myself, it’s all a bit Noddy to Big Ears.
[13/01/0033] [round 3] [works in healthcare]
Reassurance
Participants described a sense of fear around stopping 
antidepressants. This has been reported in previous 
qualitative studies of patient and health professional 
perspectives on stopping.10 Participants in this study often 
reported feeling reassured by information in ADvisor. 
While participants differed in terms of which particular 
piece of information they found reassuring, some partici-
pants noted feeling reassured knowing that they could go 
back on their antidepressant if they felt necessary. Other 
participants found that knowing that withdrawal symp-
toms are often short- lived offered reassurance.
Well that’s a good section because that is quite a wor-
ry, I think, for anybody wanting to come off them; it 
would worry me what would my side- effects be and 
how would I feel coming off them. So to actually—I 
mean I didn’t know this—to actually say that they are 
often short lived and go away in a few days or weeks is 
quite encouraging, isn’t it.
[04/01/0025] [round 3]
As fear of withdrawal symptoms was highlighted in the 
qualitative work, withdrawal symptoms were discussed at 
several points during the introduction module. However, 
participants who were not initially concerned about 
withdrawal symptoms felt that this was setting an expec-
tation for difficulty withdrawing. While not minimising 
withdrawal- related problems, we, therefore, revised 
the language around concerns about withdrawal in the 
introduction.
Well it’s very obvious withdrawal is a problem, look-
ing at all the advice you can see to help you get over 
it, which—yes. There’s a negative feeling there, if it’s 
stressed to this degree on this program, then you’re 
obviously expecting trouble.
[10/03/0003]
Credibility of the information appeared to be impor-
tant for participants. Participants liked to see the evidence 
base that was provided in ADvisor and in particular liked 
that it would be used within an NHS setting. The NHS 
affiliation seemed to provide a sense of reliability and 
credibility.
I’d be really pleased if they [GP/nurse] referred me 
to a website, especially if it was from the GP, because I 
think, well, it’s backed up or supported by them.
[14/03/0001] [round 1]
There was a balance that needed to be struck between 
portraying information as credible and maintaining a 
warm and friendly tone. Participants reported some of 
the information in ADvisor as sounding academic and 
reading like it could be used by practitioners. As a result, 
the tone was revised to be warmer and friendlier, while 
maintaining a sense of credibility.
It’s just very business- like so very much like maybe 
something that a university would produce or may-
be that a medical professional would share amongst 
themselves and your everyday person who’s maybe 
not used to reading things in so much detail any 
more, sadly. It’s quite dry.
[14/03/0001] [round 1]
Utility of information
Participants described the information on withdrawal 
symptoms to be useful, in particular, some participants 
liked the information on how to distinguish between signs 
of relapse and withdrawal symptoms. One participant in 
particular expressed a shift in her views on discontinuing 
as a result of the information in ADvisor. She explained 
that had she known that withdrawal symptoms may feel 
like relapse and will pass, she may have persisted with her 
lower dose of antidepressant for longer. She also high-
lighted that difficulty in getting a GP appointment is a 
barrier for her to persist with discontinuing in the face of 
difficulties.
… I didn’t know … withdrawal symptoms might ap-
pear the same as the symptoms that led to needing 
antidepressants in the first place, but they will pass 
after a short time; I didn’t know that. I thought if you 
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started feeling down again, then you were heading 
for a crash.
[13/03/0001] [round 2]
Some participants described wanting more detailed 
information about what withdrawal symptoms might be 
expected. However, on discussion with the broader study 
team, it was decided to avoid setting expectations around 
particular symptoms as this may lead patients to experi-
ence expected symptoms. Patients can instead request 
this information from their GP if it is something they feel 
they would rather know about. While this information is 
provided to GPs as part of our health professional inter-
vention package, it must be acknowledged that there are 
limitations around access to GP appointments, which may 
act as a barrier to getting information about withdrawal 
symptoms.
Participants also noted that it was useful to reflect on 
the side effects of taking antidepressants. There was an 
awareness that these can be hard to recognise, and three 
participants reported that after reading the information 
in ADvisor, they may in fact have been experiencing side 
effects of which they were previously unaware. One partic-
ipant described how this made him even more inclined to 
discontinue.
Well, as I look at these, I think maybe I’m wrong; may-
be I am still getting side- effects, but I’ve just learned 
to accept them or—I’m just a little bit in denial and 
it makes me want to get off them even more, be-
cause then—lots of these things will, you know, will 
disappear.
[12/03/0003] [round 1]
Teaching of useful skills
Participants reported the skills included in ADvisor as 
being useful. In particular, advice around preventing 
relapse and mindfulness- based skills were considered to 
be useful.
Your triggers, recognising your emotions and remind-
ing yourself that you don’t have to react in a certain 
way; you can react in a different way. Yes, I think it’s 
very good.
[13/01/0001] [round 2]
Acceptance of difficulties and of emotions was discussed 
as a useful coping strategy by participants, both with 
regards to their own pre- existing relationship to their 
emotions, and with regards to the messages in ADvisor 
on acceptance.
When you read it like that, it is true; the more you 
worry about things, the more down you get. So you’ve 
got to learn to stop doing that. I have to start putting 
that into practice if I’m going to do this.
[13/01/0058] [round 3]
Participants liked having tools and techniques in 
ADvisor for dealing with difficult emotions and life 
stresses. There was an understanding that life stress is 
often unavoidable, and participants expressed a desire 
to learn ways of dealing with stresses. Some participants 
stated that learning how to manage emotions would act 
as a replacement for taking antidepressants.
I think that exercise of sitting by the stream is 
very good, because I know when I had Cognitive 
Behavioural Therapy I was taught to—you know—
when your thoughts came—to—and I still do this 
now—is always remember—say to yourself that it will 
pass, those feelings will pass and it might be horrible 
while you’re going through those feelings, but find 
somewhere nice and comfortable to sit, with a blan-
ket even, and that sort of thing.
[04/01/0025] [round 3]
By the final interviews in the final round, participants’ 
comments were positive with no new issues being iden-
tified. This signified the intervention was now ready for 
further evaluation and feedback in the planned feasibility 
trial to follow.
DIsCussIOn
We developed a digital intervention to support appro-
priate antidepressant discontinuation. The interven-
tion was developed through a process of triangulation 
between quantitative and qualitative review evidence, 
theory and in- depth qualitative research. ‘ADvisor' is 
designed to support ways of understanding antidepres-
sants and to help people to withdraw more successfully. 
It provides resources to build confidence for, and to 
support, stopping including side effect management, 
addressing concerns, depression relapse prevention 
and stress management. The application of the PBA22–24 
has ensured our intervention is grounded a rich under-
standing of patients’ psychosocial context.
Discontinuation can be complex,10 and the digital 
ADvisor intervention is designed to be an information- 
based resource to support patients, alongside monitoring 
and review from their (GP, family doctor). A separate 
digital intervention has been developed for GPs and 
other primary care professionals, called ‘ADvisor: Health 
Professionals’. The patient intervention will also be used 
with additional brief telephone guidance (up to an hour, 
spread over three calls by trained psychological practi-
tioners), to support use of the material. Guided digital/
internet- based resources have been found to be consis-
tently more effective than unguided digital interventions37 
for mental health problems. Guidance in this context is 
especially important as patients are withdrawing from 
pharmacotherapy, thus close monitoring is necessary.
The intervention will be implemented in a feasibility 
randomised controlled trial, where we will carry out a 
full qualitative38 and quantitative35 process study. We will 
explore how people engage with the intervention and 
how it affects their discontinuation experience. On this 
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basis, as in the latter stages of the PBA,24 we will continue 
to modify the intervention ahead of a fully powered main 
trial.
There are some limitations to consider. Our recruit-
ment for our qualitative work was from a limited, rela-
tively affluent, geographical area in the south of England. 
The majority of our participants were women in both the 
primary qualitative work and the think- aloud interviews. 
While this does reflect the higher rates of antidepressant 
use for depression in women,39 it may be that our findings 
do not accurately reflect the views of men on long- term 
antidepressants. In the think- aloud interview sample, 
only 9 of the 15 participants were taking antidepressants 
long term for depression or low mood. The intervention 
contains information on preventing depression relapse 
and focuses on the symptoms of depression and anxiety 
which may not be applicable to these individuals. As such, 
some members of our sample may not have adequately 
represented the target population for this intervention, 
which may have introduced bias in our findings. The 
average age of participants in our think- aloud interview 
sample was 55.2 years, which may be a reflection of the 
typical populations in the geographical locations in this 
study. In the feasibility trial and main trial phases of inter-
vention testing, further qualitative work will be carried 
out with a larger and demographically wider population 
of patients from a range of different areas in the UK.
The researchers conducting the think- aloud interviews 
were involved in the development of the intervention. 
This may have resulted in bias when asking questions 
about the intervention. However, in think- aloud inter-
views, the patients often express their views in response to 
what they see on the page as opposed to solely responding 
to questions from the researcher. While prompting 
and follow- up questions might have been affected by 
researcher bias, patients were not aware the interviewers 
had designed and written elements of the intervention 
and were encouraged to provide both positive and nega-
tive feedback to the researchers.
To conclude, psychologically informed interventions 
may improve the chances of effective discontinuation 
from antidepressants. ADvisor is a theory, evidence and 
person- based digital intervention that may provide this 
support. The feasibility, clinical and cost- effectiveness of 
ADvisor now needs to be determined.
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